What development phase is CLOMACRAN PHOSPHATE in?

CLOMACRAN PHOSPHATE is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

CLOMACRAN PHOSPHATE

FDA-approved withdrawn Small molecule Quality 2/100

Clomacran Phosphate is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a significant competitive advantage due to its patent protection until 2028. The primary risk is the potential increase in competition post-patent expiry in 2028.

At a glance

Generic name	CLOMACRAN PHOSPHATE
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CLOMACRAN PHOSPHATE CI brief — competitive landscape report
CLOMACRAN PHOSPHATE updates RSS · CI watch RSS